
07/07/2025
Something to be aware of with weight-loss drugs:
"Labeling for GLP-1 receptor agonists such as semaglutide and tirzepatide include warnings about the increased risk for diabetic retinopathy in patients with type 2 diabetes. The label for the combination of phentermine and topiramate (Qsymia) warns of a risk for acute myopia and secondary angle-closure glaucoma, and the label for the combination of naltrexone and bupropion (eg: Contrave) lists the risk for angle-closure glaucoma."
Although GLP-1 drugs make headlines for vision risks, other weight-loss medications carry their own eye-related side effects.